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Introduction: 
Although permanent hypoparathyroidism after thyroid or parathyroid surgery 
rarely happens in general practice, it is a difficult clinical problem. Long-term 
parathyroid hormone (PTH) therapy is rarely applied nowadays because PTH has very 
short half life (2-4 min.) and must be injected daily [1 - 3]. Gene therapy for 
hypoparathyroidism through gene transfer to skeletal cells or stem cell has been 
previously reported [4 - 6]. Although long-term gene therapy of hypoparathyroidism 
with stem cells recombined with parathyroid hormone gene and retroviral vectors has 
been reported previously [6], we conducted this study to optimize the gene therapy of 
hypoparathyroidism with a stem cell-line without viral vectors. 
Animals: 
Male Spraque-Dawley rats (about 300 gm) were used throughout this experiment. 
The animals were purchased from the National Science Council animal center and 
housed in Chang Gung Memorial Hospital at Kaohsiung, Taiwan. This study was 
performed in accordance with the guidelines provided by the experimental animal 
laboratory and approved by the animal care and use committee. The rats could access 
to food and water ad libitum and were housed in a controlled environment at a 
temperature of 24±1℃, a humidity of 55±5%, and a circadian light rhythm of 12 hr. 
Three groups were designed as followed: parathyroidectomy treated with the 
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TheraCyte encapsulated 4x107 cells, which were transfected with PTH (1-34) cDNA 
as the study group (group A, n=9); parathyroidectomy treated with the subcutaneous 
injection of 4x107 cells, which were transfected with PTH (1-34) cDNA as the 
subcutaneous injection group (group B, n=9); and parathyroidectomy treated with 
nothing as the control group (group C, n=10). 
Results 
All rats in group A survived well with normal appetites and activities. Two of 9 
rats in group B and also 3 of 10 rats in group C died as a result of exhaustion within 
one month after parathyroidectomy. Serum levels of calcium in group A were 
significantly higher than in both groups B and C (all ≦ 0.003) (Table 1). Serum levels 
of phosphorus in group A were significantly lower than in both groups B and C (all p 
≦ 0.002) (Table 2). Serum levels of PTH (1-34) in group A were significantly higher 
than in both groups B (p = 0.004) and C (p = 0.003) (Table 3). In group A, both serum 
calcium and PTH (1-34) levels were significantly higher at 2, 3, and 4 months 
post-treatment than at baseline (0-month) (all p ≦ 0.022) (Table 1 and Table 3). In 
group A, serum phosphorus levels were lower at 1, 2, 3, and 4 months post-treatment 
than at baseline (all p < 0.001) (Table 2). Hematoxylin and eosin staining showed live 
cells in the TheraCyte (Fig. 1A), and immunohistochemical staining demonstrated 
PTH (1-34)-positive cells in the TheraCyte-encapsulated 4x107 cells (Fig. 1B). No 
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PTH (1-34)-positive cells could be found in the subcutaneous tissue of group B (Fig. 
2A, 2B). PTH (1-34) mRNA (179 bp) was detected in C3H/10T1/2 cells 48 hr after 
PTH (1-34) cDNA transfection by Lipofectamine and also in cells 48 hr after G148 
treatment. PTH (1-34) mRNA could not be detected either in the C3H/10T1/2 cells 
without transfection of PTH (1-34) cDNA, nor cells after G418 treatment (Fig. 3 
A,B,C,D). Before loading to the TheraCyte, many PTH (1-34)-positive C3H/10T1/2 
cells survived after PTH (1-34) cDNA transfection and G418 treatment and only a few 
cells survived after G148 treatment without transfection (Fig. 4A, 4B). 
Discussion: 
Mesenchymal stem cells have been used as a carrier for conditionally replicating 
adenoviruses to target metastatic breast cancer in vivo [7] or as a vehicle for oncolytic 
adenoviruses [8,9]. Mesenchymal stem cells-mediated gene delivery of bone 
morphogenetic protein-2 also has been reported to induce bone formation and to heal 
bone fracture [10, 11]. We used the C3H/10T1/2 cell-line, which was established in 
1972 from 14-and 17-day old C3H mouse embryos [12], as the gene therapy of 
hypoparathyroidism. These cells displayed fibroblastic morphology in cell culture and 
were functionally similar to mesenchymal stem cells. Inhibiting methylation with 
5-azacytidine in C3H/10T1/2 cells produces cells that exhibit stable morphological 
and biochemical features of muscle, adipose, bone, or cartilage cells. After 
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transfection of PTH (1-34) cDNA into C3H/10T1/2 cells using Lipofectamine 2000, 
PTH (1-34) mRNA could be found in cells and they could survive after G148 
treatment. TherayCyte devices consist of an inner membrane of 
polytetrafluoroethylene (PTFE) that is 30 µm thick and has a 0.4-µm pore size which 
prevents the entry of cells into the device but allows the entry of antibodies and 
compliment factors. The outer membrane is a laminated 15-µm-thick PTFE layer 
which has a 5-µm pore size that allows improved biocompatibility and induces 
vascularization. We used a 20-µl device to load 4x107 live cells in a volume of 1 ml. 
After implantation of the TheraCyte-encapsulated 4x107 C3H/10T1/2 cells, 
which were recombined with PTH (1-34) cDNA, we found that the live cells could 
secrete PTH (1-34) as documented in our study of live human parathyroid cells [13]. 
Serum calcium and PTH (1-34) levels increased significantly 2 months later and could 
be maintained for up to 4 months. Serum calcium and PTH (1-34) levels in the study 
group were significantly higher than in the subcutaneous injection group and also 
higher than in the control group. Serum levels of phosphorus decrease significantly 1 
month later and could be maintained for up to 4 months. Serum phosphorus levels 
were significantly lower in the study group than in the subcutaneous injection group 
and also lower than in the control group. Four months after subcutaneous injection of 
C3H/10T1/2 cells, which were recombined with PTH (1-34) cDNA, neither PTH 
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(1-34)-positive cells nor tumor cells could be found at the injection site. It was 
thought that C3H/10T1/2 cells transfected with PTH (1-34)-cDNA were all rejected 
and destroyed by the host rat after the subcutaneous injection. We therefore, conclude 
that stem cells can be used for gene therapy of hypoparathyroidism. After 
implantation of the TheraCyte-encapsulated stem cells recombined with PTH (1-34) 
cDNA, cells seem to function very well. The TheraCyte can prevent cells from 
rejection, dissemination or tumor formations. 
Materials and Methods: 
Plasmid DNA: 
The plasmid carrying full-length human PTH (1-34) that was under the control of 
a human cytomegalovirus promoter (pcDNA3) was cloned. We chose pcDNA3 as a 
vector (Mission Biotech, Taipei, Taiwan). The PTH (1-34) gene (179 bps) was 
inserted into pcDNA3 (5.4 Kb) via the Hind III, Bam HI cloning sites, and competent 
Escherichia coli. cells were used to amplify the cDNA. The cDNA concentratons was 
measured by ultraviolet absorption at 260 nm. 
Stem cells: 
C3H/10T1/2 stem cells were plated at a low density, and cultured in DMEM 
containing 10% Fetal Bovine Serum with Antibiotic-Antimycotic (GIBCO, Grand 
Island, N.Y. U.S.A.) for 48-72 hr at 37℃ in an incubator containing 5% CO2 at 75 
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cm2 flasks. 
Gene transfection: 
C3H/10T1/2 cells were seeded at 6-well plates at 80-90 confluence in the 
appropriate amount of growth median without antibiotics and transfected with 2 
ug/well plasmid DNA using Lipofectamine 2000 (Invitrogen, Bio Vision, Inc. 
Mountain View, CA), at the ratio of 1:3 (vol./vol.). After transfection for 24 hr, the 
cells were transferred, and cultured in DMEM containing 10% Fetal Bovine Serum 
with Antibiotic-Antimycotic. Forty-eight hr after transfection the transfected cells 
were grown in DMEM containing G418 (GIBCO, Grand Island, NY) at 30 mg/ml 
until all of the non-transfected cells were dead (1 week). The gene expression of stem 
cells was confirmed by reverse transcription-polymerase chain reaction (RT-PCR). 
Live cells containing PTH (1-34) cDNA at the density of 4x107 were loaded into the 
TheraCyte, using the centrifugation loading method according to the users’ manual 
(TheraCyte Inc. Irvine, CA). In group A, after parathyroidectomy, the 
TheraCyte-encapsulated 4 x 107 live stem cells containing PTH (1-34) cDNA, were 
implanted to the subcutaneous tissue of rats’ back. In group B, after 
parathyroidectomy, live stem cells containing PTH (1-34) cDNA at the density of 
4x107 were injected directly to the subcutaneous tissue of rats’ xiphoid processes. In 
group C, nothing was given after parathyroidectomy. 
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Detection of PTH (1-34) mRNA with RT-PCR in stem cells: 
Total RNA from the transfected stem cells was extracted with TRI-Zol reagent 
(Invitrogen Life Technologies, Carlsbad, CA) according to the manufacturers’ 
instructions. cDNA was prepared with Superscript II Reverse Transcriptase 
(Invitrogen Life Technologies) and stored at -20℃. A 179 bp segment of the PTH 
(1-34) gene was amplified by PCR as described below. 
Sequences of the primer pair of amplification of the transferred gene were 
5’-CCATGTACGTAGCCATCCAG-3’ and 5’-GCACGATTTCCCTCTCAGCTGT-3’ 
(custom synthesized by Life Technologies Burlington, Ontario, Canada). Reactions 
were carried out under the following conditions: 94℃ for 5 min. followed by 30 
cycles at 94℃ for 30 sec., 51.6℃ for 30 sec., 72℃ for 30 sec., 72℃ for 7 sec. and 
4℃ to terminate the reaction. The PCR products were separated by electrophoresis on 
2% agarose gels, and stained with ethidium bromide to visualize the bands. β-actin 
was used as an internal control. 
Serum levels of calcium, phosphorus and PTH (1-34) determinations: 
Blood samples were collected to determine calcium, phosphoruse and PTH (1-34) 
levels at baseline, 1 month, 2 months, 3 months and 4 months after treatment. Serum 
levels of PTH (1-34) were measured by enzyme-linked immunosorbent assay (ELISA) 
with a human PTH (1-34) kit (Peninsula Laboratories, San Carlos, CA). The minimal 
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detectable concentration was 0.04-0.06 ng/ml, and the detectable range was 0-25 
ng/ml. Serum levels of calcium and phosphorus were measured by a cresophthalein 
complexion and phosphomolybdate UV method. 
Parathyroidectomy: 
Under sodium pentothal anesthesia, a longitudinal skin incision was made at the 
anterior part of neck. The right and left parathyroid glands were exposed and removed 
under microscopic examination (x16). After this procedure the rats were returned to 
the animal center, to recover until the experiment. 
Immunohistochemical staining with PTH (1-34) antibody:  
Four months after implantation, the TheraCyte-encapsulated 4x107 cells was 
removed from the rats’ back and sent for the histological examination. Four months 
after subcutaneous injection of 4x107 cells (group B), the rats’ skin and subcutaneous 
at xiphoid process was excised for the histological examination. After 
formalin-fixation, the TheraCyte and tissues were deparaffinized in xylene and 
dehydrated in a graded ethanol series. An endogenous peroxidase was quenched with 
3% hydrogen peroxide in methanol. After incubation of the tissue with rabbit 
anti-human parathyroid hormone (1-34) serum (dilated 1:6000, Phoenix 
Pharmaceuticals, Belmont, CA), horseradish peroxidase (Zymed 
Laboratories/Invitrogen, San Francisco, CA) was added, and after a wash step, 
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diaminobenzidine was then added. The peroxidase then catalyzed the substrate and 
converted the chromogen diaminobenzidine to a brown-colored deposit. 
Statistical analysis was performed with the Statistical Product and Service 
Solution (SPSS) version 11.5 software package (SPSS, Chicago, IL). All data are 
expressed as mean ± SD. The paired t-test and a repeated measures of analysis of 
variance were used for inter-group analysis. To determine whether a group was 
significantly different from the others, simultaneous multiple comparison were 
conducted using Bonferroni techniques. A p value less than 0.05 was considered 
significant. 
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Table 1. Serum calcium levels (mg/dl) after parathyroidectomy: at baseline and 
1-month, 2-month, 3-month and 4-month after therapy in various groups. 
               Month 
Groups 
Baseline 1-month 2-month 3-month 4-month 
Group A 
(TheraCyte-encapsulated 
4x107 cells) (N=9) 
4.4±0.43
5.6±0.74＋ 7.0±0.64# 7.9±1.10# 8.5±1.50# 
Group B☆ 
(Subcutaneous injection of 
4x107 cells) (N=7) 
5.0±0.82 5.1±0.97 5.2±0.51 5.7±1.07 5.1±0.44 
Group C△ 
(Control) (N=7) 
4.2±1.24 3.7±1.00 4.0±1.25 3.8±1.13 3.8±1.03 
All data=mean±SD 
△☆Using repeated measures ANOVA and ＋ #paired t-test 
☆P = 0.003 compared with group A 
△P < 0.001 compared with group A 
＋P = 0.0012 compared with baseline 
#P < 0.001 compared with baseline 
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Table 2. Serum phosphorus levels (mg/dl) after parathyroidectomy: at baseline and 
1-month, 2-month, 3-month and 4-month after therapy in various groups. 
               Month 
Groups 
Baseline 1-month 2-month 3-month 4-month 
Group A 
(TheraCyte-encapsulated 
4x107 cells) (N=9) 
12.7±1.91 
11.1±1.81＋ 10.2±0.89＋ 8.8±1.64＋ 8.4±1.94＋ 
Group B☆ 
(Subcutaneous injection of 
4x107 cells) (N=7) 
12.5±1.70 11.9±1.57 12.3±1.33 12.6±1.61 13.3±2.60 
Group C△ 
(Control) (N=7) 
11.4±1.38 13.2±1.01 12.4±1.78 13.4±1.72 12.7±1.79 
All data=mean±SD 
☆△Using repeated measures ANOVA and ＋paired t-test 
☆P=0.002 compared with group A 
△P=0.001 compared with group A 
＋P<0.001 compared with baseline 
 
 
 
 
 
 
 
 
 
 
 
 
 2
 
 1 
Table 3. Serum PTH (1-34) (ng/ml) levels after parathyroidectomy: at the baseline and 
1-month, 2-month, 3-month and 4-month after therapy in various groups. 
               Month 
Groups 
Baseline 1-month 2-month 3-month 4-month 
Group A 
(TheraCyte-encapsulated 
4x107 cells) (N=9) 
0.13±0.03 
0.39±0.48＋ 2.1±2.07# 3.1±2.644## 2.9±2.556### 
Group B☆ 
(Subcutaneous injection of 
4x107 cells) (N=7) 
0.13±0.037 0.15±0.049 0.28±0.277 0.21±0.140 0.20±0.152 
Group C△ 
(Control) (N=7) 
0.12±0.029 0.11±0.026 0.10±0.04 0.13±0.045 0.11±0.019 
All data=mean±SD 
☆△Using repeated measures ANOVA and ＋ # ## ###paired t-test 
☆P=0.004 compared with group A 
△P=0.003 compared with group A 
＋P=0.119 compared with baseline 
#P=0.022 compared with baseline 
##P=0.010 compared with baseline 
###P=0.011 compared with baseline 
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